These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 27399956)

  • 1. A Randomized, Comparative Study to Evaluate Efficacy and Safety of Two Injection Volumes of AbobotulinumtoxinA in Treatment of Glabellar Lines.
    Punga AR; Alimohammadi M; Fagrell D; Nyberg F; Rees D; Wong C
    Dermatol Surg; 2016 Aug; 42(8):967-76. PubMed ID: 27399956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AbobotulinumtoxinA for reduction of glabellar lines in patients with skin of color: post hoc analysis of pooled clinical trial data.
    Taylor SC; Callender VD; Albright CD; Coleman J; Axford-Gatley RA; Lin X
    Dermatol Surg; 2012 Nov; 38(11):1804-11. PubMed ID: 22928999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ready-to-use abobotulinumtoxinA solution versus powder botulinumtoxinA for treatment of glabellar lines: Investigators' and subjects' experience in a Phase IV study.
    Chadha P; Gerber PA; Hilton S; Molina B; Haq S; Partridge J; Wong V; Hoffmann K; Persson C; Prygova I
    J Cosmet Dermatol; 2024 Sep; 23(9):2857-2866. PubMed ID: 38807515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of AbobotulinumtoxinA for Treatment of Moderate-to-Severe Glabellar Lines: A Meta-Analysis.
    Han X; Bai J; Kuang J
    Ophthalmic Plast Reconstr Surg; 2024 Mar-Apr 01; 40(2):126-133. PubMed ID: 38319153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Two-Stage Injection Technique and Dose-Ranging Study Using High-Dose AbobotulinumtoxinA for Treating Platysmal Bands.
    Joseph JH; Foulad A; Hsue VB; Romero T; Davis P
    J Drugs Dermatol; 2024 Jan; 23(1):1311-1318. PubMed ID: 38206150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of action of abobotulinumtoxina and onabotulinumtoxina: a randomized, double-blind study using a contralateral frontalis model.
    Nestor MS; Ablon GR
    J Clin Aesthet Dermatol; 2011 Sep; 4(9):43-9. PubMed ID: 21938269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines.
    Monheit GD; Baumann L; Maas C; Rand R; Down R
    Dermatol Surg; 2020 Jan; 46(1):61-69. PubMed ID: 31356432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Assessment of 2 Licensed AbobotulinumtoxinA Injection Volumes for the Treatment of Glabellar Lines.
    Kaufman J; Cohen JL; Peredo MI; Jonas B; Down R; Nogueira A
    Dermatol Surg; 2019 Oct; 45(10):1274-1284. PubMed ID: 30893159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of EB-001, a Novel Type E Botulinum Toxin, in Subjects with Glabellar Frown Lines: Results of a Phase 2, Randomized, Placebo-Controlled, Ascending-Dose Study.
    Yoelin SG; Dhawan SS; Vitarella D; Ahmad W; Hasan F; Abushakra S
    Plast Reconstr Surg; 2018 Dec; 142(6):847e-855e. PubMed ID: 30489516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trial.
    Ascher B; Kestemont P; Boineau D; Bodokh I; Stein A; Heckmann M; Dendorfer M; Pavicic T; Volteau M; Tse A; Picaut P; Rzany B
    Aesthet Surg J; 2018 Feb; 38(2):183-191. PubMed ID: 28200002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, Patient-Reported Outcomes, and Safety in Male Subjects Treated With OnabotulinumtoxinA for Improvement of Moderate to Severe Horizontal Forehead Lines.
    Keaney TC; Cavallini M; Leys C; Rossi A; Drinkwater A; Manson Brown S; Garcia JK; Mao C
    Dermatol Surg; 2020 Feb; 46(2):229-239. PubMed ID: 31343446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Prabotulinumtoxin A and Onabotulinumtoxin A for Crow's Feet: A Phase 3, Multicenter, Randomized, Double-Blind, Split-Face Study.
    Cheon HI; Jung N; Won CH; Kim BJ; Lee YW
    Dermatol Surg; 2019 Dec; 45(12):1610-1619. PubMed ID: 30893169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 3 Study of OnabotulinumtoxinA Distributed Between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial Lines.
    De Boulle K; Werschler WP; Gold MH; Bruce S; Sattler G; Ogilvie P; Street J; Larsen KE; Yushmanova I; Lei X; Lee E; Vitarella D; Mao C
    Dermatol Surg; 2018 Nov; 44(11):1437-1448. PubMed ID: 30096106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines in Male Subjects: Post-Hoc Analyses From Randomized, Double-Blind Pivotal Studies.
    Jones DH; Kerscher M; Geister T; Hast MA; Weissenberger P
    Dermatol Surg; 2017 Nov; 43 Suppl 2():S235-S241. PubMed ID: 29064991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Subject and Physician Satisfaction after Long-Term Treatment of Glabellar Lines with AbobotulinumtoxinA (Dysport
    Gubanova E; Haddad Tabet M; Bergerova Y; Moiseieva O; Chemeris A; Sanches E; Sharova A; Rodriguez Pose L; Raymond R; Prygova I; Carlisle I
    Aesthetic Plast Surg; 2018 Dec; 42(6):1672-1680. PubMed ID: 30120518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Keeping up appearances: Don't frown upon the effects of botulinum toxin injections in facial muscles.
    Punga AR; Alimohammadi M; Liik M
    Clin Neurophysiol Pract; 2023; 8():169-173. PubMed ID: 37681120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subject satisfaction and psychological well-being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines.
    Dayan S; Joseph J; Moradi A; Lorenc ZP; Coleman K; Ablon G; Kaufman-Janette J; Cox SE; Campbell A; Munavalli G; Prygova I
    J Cosmet Dermatol; 2022 Jun; 21(6):2407-2416. PubMed ID: 35266281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin type A for facial wrinkles.
    Camargo CP; Xia J; Costa CS; Gemperli R; Tatini MD; Bulsara MK; Riera R
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD011301. PubMed ID: 34224576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Satisfaction with AbobotulinumtoxinA for Aesthetic Use in the Upper Face: A Systematic Literature Review and
    Smit R; Gubanova E; Kaufman J; Landau M; Molina B; Andriopoulos B; Maisonobe P; Prygova I; Redaelli A
    J Clin Aesthet Dermatol; 2021 Feb; 14(2):E69-E88. PubMed ID: 34221231
    [No Abstract]   [Full Text] [Related]  

  • 20. Onset and Duration of AbobotulinumtoxinA for Aesthetic Use in the Upper face: A Systematic Literature Review.
    Nestor M; Cohen JL; Landau M; Hilton S; Nikolis A; Haq S; Viel M; Andriopoulos B; Prygova I; Foster K; Redaelli A; Picaut P
    J Clin Aesthet Dermatol; 2020 Dec; 13(12):E56-E83. PubMed ID: 33488922
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.